Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAL-D3
- Development stage
- Unknown
- Lead developer
- Anglo-French Drugs & Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KAL-D3 is an oral fixed-dose combination supplement developed and marketed by Anglo-French Drugs & Industries. It is formulated with calcium carbonate (providing elemental calcium), vitamin D3 (cholecalciferol), and soy isoflavones. The supplement is indicated for the management of weak and brittle bones, osteoporosis, calcium and vitamin D3 deficiencies, and for boosting immunity. Calcium carbonate provides the essential mineral required to maintain bone density and skeletal structure. Vitamin D3 enhances the intestinal absorption of calcium, ensuring its efficient utilization in bone mineralization. Soy isoflavones act as phytoestrogens, which help attenuate bone mineral density loss (particularly in postmenopausal women) and provide antioxidant, anti-inflammatory, and antimicrobial properties that support the immune system.
- Brand names
- KAL-D3KAL-D-3KAL-D 3KAL-D3 TabletsKAL-D-3 TabletsKAL-D 3 Tablets
- Other names
- calcium + isoflavones + vitamin D3calcium carbonate + isoflavones + cholecalciferolisoflavone + calcium + vitamin D3isoflavone, vitamin D3 & calcium tablet
02
Targets
CaSR (Extracellular calcium-sensing receptor)ESR1 (ERα)ESR2 (ERβ)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on KAL-D3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAL-D3.